Bone Dysplasia Sclerosteosis Results from Loss of the SOST Gene Product, a Novel Cystine Knot–Containing Protein
Open accessThe DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index.
Abstract
Sclerosteosis is an autosomal recessive sclerosing bone dysplasia characterized by progressive skeletal overgrowth. The majority of affected individuals have been reported in the Afrikaner population of South Africa, where a high incidence of the disorder occurs as a result of a founder effect. Homozygosity mapping in Afrikaner families along with analysis of historical recombinants localized sclerosteosis to an interval of approximately 2 cM between the loci D17S1787 and D17S930 on chromosome 17q12-q21. Here we report two independent mutations in a novel gene, termed "SOST." Affected Afrikaners carry a nonsense mutation near the amino terminus of the encoded protein, whereas an unrelated affected person of Senegalese origin carries a splicing mutation within the single intron of the gene. The SOST gene encodes a protein that shares similarity with a class of cystine knot-containing factors including dan, cerberus, gremlin, prdc, and caronte. The specific and progressive effect on bone formation observed in individuals affected with sclerosteosis, along with the data presented in this study, together suggest that the SOST gene encodes an important new regulator of bone homeostasis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Mutations in genes that have highly enriched expression in osteocytes cause rare bone and mineral disorders.”
From Osteocyte transcriptome mapping identifies a molecular landscape controlling skeletal homeostasis and susceptibility to skeletal disease (2021) · cites this paper as [17]
Citations
Cites
Bone: Formation by Autoinduction
Urist, M. R. (1965) · Science · doi:10.1126/science.150.3698.893 · Cited by 5,546 · cited 1×
“Although this family of morpho-gens was originally identified on the basis of bone-in-ducing activity (Urist 1965), a number of these factors have been shown to be critical for very early stages of embryogenesis and fetal development.”
Prediction of complete gene structures in human genomic DNA
Burge, C., & Karlin, S. (1997) · Journal of Molecular Biology · doi:10.1006/jmbi.1997.0951 · Cited by 4,228 · cited 8×
“The novel variant gene (designated “P50gsc3”) predicted by GENSCAN was located between markers D17S951 and D17S1860 (fig.”
InfluentialA comprehensive genetic map of the human genome based on 5,264 microsatellites
Dib, C., Fauré, S., Fizames, C., Samson, D., Drouot, N., Vignal, A., Millasseau, P., Marc, S., Kazan, J., Seboun, E., et al. (1996) · Nature · doi:10.1038/380152a0 · Cited by 2,928 · cited 3×
“D17S1793, D17S1789, D17S951, and D17S1860 within the critical region bounded by D17S1787 and D17S930, an interval of ∼ 2 cM (Dib et al. 1996) on the cytogenetic border between the chromosomal bands 17q12–q21.”
Bone morphogenetic proteins: multifunctional regulators of vertebrate development.
Hogan, B. L. (1996) · Genes & Development · doi:10.1101/gad.10.13.1580 · Cited by 1,962
Therapeutic Approaches to Bone Diseases
Rodan, G. A., & Martin, T. J. (2000) · Science · doi:10.1126/science.289.5484.1508 · Cited by 1,767 · cited 1×
“Currently there is no effective treatment for the restoration of normal bone mass in individuals with pathologically low skeletal density, and there is a large unmet need for therapy that can increase bone deposition in osteoporosis (Rodan and Martin 2000).”
BackgroundEasy calculations of lod scores and genetic risks on small computers.
Lathrop, M. G., & Lalouel, J.-M. (1984) · Europe PMC (PubMed Central) · Cited by 1,526
Faster sequential genetic linkage computations.
Cottingham, R. W., Idury, R. M., & Schäffer, A. A. (1993) · Europe PMC (PubMed Central) · Cited by 1,364
Nonsense-mediated mRNA decayin health and disease
Frischmeyer, P. A. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.10.1893 · Cited by 992 · cited 1×
“The relatively low levels of mutant transcripts observed could be the result of nonsense-mediated mRNA decay, as the inclusion of intronic sequence introduced an in-frame nonsense codon (Frischmeyer and Dietz 1999; Hentze and Kulozik 1999).”
BackgroundHomozygosity Mapping: A Way to Map Human Recessive Traits with the DNA of Inbred Children
Lander, E. S., & Botstein, D. (1987) · Science · doi:10.1126/science.2884728 · Cited by 875
FORMATION AND FUNCTION OF SPEMANN'S ORGANIZER
Harland, R., & Gerhart, J. (1997) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.13.1.611 · Cited by 839 · cited 1×
“In addition, the requirement for the coordinated expression of negative regulators of BMP activity, such as noggin and chordin, as well as members of the dan family, has been well described (Harland and Gerhart 1997; Sasai and De Robertis 1997; Hsu et al. 1998).”
Background
Research works printed but not linked: 3
- Gardner J (1999) Profound childhood deafness in South Africa: a clinical and molecular genetic approach. Ph.D. thesis, University of Cape Town, Cape Town
- Hausen, 1967, Sklerosteose, Vol. 6, 351
- Peitruschka, 1958, Weitere Mitteilungen über die Marmorknochenkrankheit (Albers-Schonbergsche Krankheit) nebst Bemerkungen zur Differentialdiagnose, Klin Monatbl, 132, 509
Cited by
Items 501–600 of 1,000
Lhaneche, L., Hald, J. D., Domingues, A., Hannouche, D., Délepine, M., Zélénika, D., Boland, A., Ostertag, A., Cohen-Solal, M. E., Langdahl, B. L., et al. (2016) · Bone · doi:10.1016/j.bone.2016.08.004 · Cited by 24
Cremers, S., & Aronson, J. (2017) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13331 · Cited by 25
Osteoporosis Therapeutics 2020
Kocijan, R., Klaushofer, K., & Misof, B. M. (2020) · Handbook of experimental pharmacology · doi:10.1007/164_2020_373 · Cited by 26
Kubota, T., Michigami, T., & Ozono, K. (2010) · Clinical Pediatric Endocrinology · doi:10.1297/cpe.19.49 · Cited by 26
Vidal, C., Cachia, A., & Xuereb‐Anastasi, A. (2009) · Bone · doi:10.1016/j.bone.2009.06.027 · Cited by 27
“Linkage studies of monogenic bone diseases revealed several chromosomal regions putting into light various genes that were never thought to be involved in bone physiology such as the low density lipoprotein receptor-related protein (LRP)-5 and sclerostin (SOST) genes [3,4].”
BackgroundBone metabolism in patients with anorexia nervosa and amenorrhoea
Idolazzi, L., Ghoch, M. E., Grave, R. D., Bazzani, P. V., Calugi, S., Fassio, S., Caimmi, C., Viapiana, O., Bertoldo, F., Braga, V., et al. (2016) · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity · doi:10.1007/s40519-016-0337-x · Cited by 24
The canonical Wnt/β-catenin pathway: From the history of its discovery to clinical application
Grebennikova, T. A., Belaya, Z. E., Rozhinskaya, L. Y., & Mel'nichenko, G. A. (2016) · Terapevticheskii arkhiv · doi:10.17116/terarkh201688674-81 · Cited by 27
Huang, J., Ma, T., Wang, C., Wang, Z., Wang, X., Hua, B., Jiang, C., & Yan, Z. (2024) · Molecular Medicine · doi:10.1186/s10020-024-00933-5 · Cited by 23
The roles of sclerostin and irisin on bone and muscle of orchiectomized rats
Zhou, B., Zhang, Q., Lin, X., Hu, J., Zhao, D., Jiang, Y., Xing, X., & Li, M. (2022) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-022-05982-7 · Cited by 23
“Studies revealed that the loss of sclerostin expression resulted in a high bone mass and increased bone strength in patients with sclerosteosis [35] and Van Buchem disease [36] as well as in sclerostin-deficient mice [37].”
BackgroundAppropriate models for novel osteoporosis drug discovery and future perspectives
Gennari, L., Rotatori, S., Bianciardi, S., Gonnelli, S., Nuti, R., & Merlotti, D. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1080685 · Cited by 23
“Of interest, subsequent genetic studies revealed the existence of different mutations within the SOST gene, encoding sclerostin, or downstream the same gene as a cause of sclerosteosis and van Buchem’s disease, respectively, two rare autosomalrecessive endosteal hyperostosis syndromes with high bone mass and absence o…”
BackgroundThe Role of Sclerostin in the Pathophysiology of Sclerosing Bone Dysplasias
van Lierop, A. H., Hamdy, N. A. T., van Bezooijen, R. L., Löwik, C. W. G. M., & Papapoulos, S. E. (2011) · Clinical Reviews in Bone and Mineral Metabolism · doi:10.1007/s12018-011-9123-5 · Cited by 23
“In addition to bone, cartilage and cementum, transcripts of SOST have also been found in kidney, liver, and heart [6, 7], but no sclerostin expression could be detected in any of these tissues in human [16].”
BackgroundDevelopments in the scientific understanding of osteoporosis
Lane, N. E., & Yao, W. (2009) · Arthritis Research & Therapy · doi:10.1186/ar2656 · Cited by 32
Kumar, R., & Vallon, V. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014020166 · Cited by 23
Serum sclerostin in high-activity adult patients with juvenile idiopathic arthritis
Maresova, K. B., Jarošová, K., Pavelká, K., & Stepan, J. J. (2014) · Arthritis Research & Therapy · doi:10.1186/s13075-014-0460-x · Cited by 25
“Sclerostin is also produced by chondrocytes and cementocytes [38,41], as well as in the liver, vascular wall and kidney [42,43].”
BackgroundCejka, D., Parada-Rodriguez, D., Pichler, S., Marculescu, R., Krämer, I., Kneissel, M., Gross, T. J., Reisinger, A., Pahr, D. H., Monier‐Faugere, M., et al. (2016) · Kidney International · doi:10.1016/j.kint.2016.06.019 · Cited by 24
“Loss-of-function mutations of sclerostin lead to a rare heritable disease named sclerosteosis, which is characterized by overgrowth of mechanically competent bone.(14,15) Inhibition of sclerostin by gene knockout (KO) or monoclonal antibodies also results in this high bone mass phenotype.”
BackgroundHuman Genetics of Sclerosing Bone Disorders
Ridder, R. D., Boudin, E., Mortier, G. R., & Hul, W. V. (2018) · Current Osteoporosis Reports · doi:10.1007/s11914-018-0439-7 · Cited by 24
Bone, a Secondary Growth Site of Breast and Prostate Carcinomas: Role of Osteocytes
Maroni, P., & Bendinelli, P. (2020) · Cancers · doi:10.3390/cancers12071812 · Cited by 26
Whyte, M. P. (2018) · Wiley eBooks · doi:10.1002/9781119266594.ch107 · Cited by 23
Effect of sclerostin removal in vivo on experimental periodontitis in mice
Yang, X., Han, X., Shu, R., Jiang, F., Xu, L., Xue, C., Chen, T., & Bai, D. (2016) · Journal of Oral Science · doi:10.2334/josnusd.15-0690 · Cited by 23
Treatment of Osteoporosis, with a Focus on 2 Monoclonal Antibodies
Chang, B., Quan, Q., Li, Y., Qiu, H., Jiang, P., & Gu, Y. (2018) · Medical Science Monitor · doi:10.12659/msm.912309 · Cited by 25
Gonzalez, M. E., Brophy, B., Eido, A., Leonetti, A. E., Djomehri, S. I., Augimeri, G., Carruthers, N. J., Cavalcante, R. G., Giordano, F., Andò, S., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-4054 · Cited by 23
Clinical Inference of Serum and Bone Sclerostin Levels in Patients with End-Stage Kidney Disease
Maré, A. D., Verhulst, A., Cavalier, E., Delanaye, P., Behets, G. J. S., Meijers, B. K. I., Kuypers, D. R. J., D’Haese, P. C., & Evenepoel, P. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8122027 · Cited by 23
“Sclerostin is a secreted glycoprotein that is encoded by the SOST gene [1,2].”
BackgroundShould We Consider the Cardiovascular System While Evaluating CKD-MBD?
Rroji, M., Figurek, A., & Spasovski, G. B. (2020) · Toxins · doi:10.3390/toxins12030140 · Cited by 24
“Interestingly, the SOST gene is found to be also expressed in other tissues and organs and, besides bone, primarily in heart, lung, aorta, and kidney [128,129].”
BackgroundRoles of osteocytes in phosphate metabolism
Michigami, T. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.967774 · Cited by 24
“The inactivation and reduced expression of SOST in humans have been shown to be responsible for rare bone sclerosing diseases, such as sclerosteosis 1 and van Buchem diseases (14).”
BackgroundEndocrine functions of sclerostin
Riddle, R. C. (2022) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2022.100433 · Cited by 23
Higher Circulating Parathormone is Associated with Smaller and Weaker Bones in Obese Children
Radetti, G., Franceschi, R., Adami, S., Longhi, S., Rossini, M., & Gatti, D. (2014) · Calcified Tissue International · doi:10.1007/s00223-014-9853-8 · Cited by 23
Boudin, E., Steenackers, E., de Freitas, F., Nielsen, T. L., Andersen, M., Brixen, K., Hul, W. V., & Piters, E. (2013) · Bone · doi:10.1016/j.bone.2013.01.014 · Cited by 23
Sclerostin expression in bone tumours and tumour‐like lesions
Inagaki, Y., Hookway, E. S., Kashima, T. G., Munemoto, M., Tanaka, Y., Hassan, A. B., Oppermann, U. C. T., & Athanasou, N. A. (2016) · Histopathology · doi:10.1111/his.12953 · Cited by 22
“In humans, SOST mRNA is expressed in the heart, aorta, and liver, and at high levels in the kidney.(10,11,16,17) In adult mouse and human bone, sclerostin expression is restricted to osteocytes, being localized around osteocyte lacunae and in dendritic processes in osteocyte canaliculi.”
BackgroundWu, T., Wang, L.-N., Dr, T., & Sun, F.-Y. (2017) · Gene Therapy · doi:10.1038/gt.2017.31 · Cited by 23
Kalousová, M., Sulková, S., Kuběna, A. A., Zakiyanov, O., Tesař, V., & Zima, T. (2019) · Physiological Research · doi:10.33549/physiolres.934034 · Cited by 22
“Sclerostin was first described in 2001 (Balemans et al. 2001, Brunkow et al. 2001) and till now (September 548 Kalousová et al. Vol. 68 13, 2018) there are more than 1570 records for key words ″sclerostin″ or ″SOST″ in the medical database Medline, 235 of which are from 2017 and the first half of…”
BackgroundInfluentialFunctional interaction between Wnt and Bmp signaling in periosteal bone growth
Song, D., He, G., Shi, Y., Ni, J., & Long, F. (2021) · Scientific Reports · doi:10.1038/s41598-021-90324-1 · Cited by 24
Recombinant sclerostin inhibits bone formation in vitro and in a mouse model of sclerosteosis
Dreyer, T. J., Shah, M., Doyle, C., Greenslade, K. J., Penney, M., Creeke, P. I., Kotian, A., Ke, H. Z., Naidoo, V., & Holdsworth, G. (2021) · Journal of Orthopaedic Translation · doi:10.1016/j.jot.2021.05.005 · Cited by 22
Midha, S., Chameettachal, S., Dey, E., & Ghosh, S. (2017) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.7b00006 · Cited by 22
Emerging and potential therapies for osteoporosis
Grey, A. B., & Reid, I. R. (2005) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.14.3.265 · Cited by 22
“Thus, deletion of the gene encoding sclerostin is associated with increased bone mass [108,109], and forced overexpression of sclerostin causes osteoporosis [107].”
BackgroundTherapeutic targeting of Wnt antagonists by small molecules for treatment of osteoporosis
Shah, A. A., Chand, D., Ahamad, S., Porwal, K., Chourasia, M. K., Mohanan, K., Srivastava, K. R., & Chattopadhyay, N. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116587 · Cited by 22
Brommage, R., Powell, D. R., & Vogel, P. (2019) · Disease Models & Mechanisms · doi:10.1242/dmm.038224 · Cited by 23
Efficacy of a sclerostin antibody compared to a low dose of PTH on metaphyseal bone healing
Agholme, F., Macias, B. R., Hamang, M., Lucchesi, J., Adrian, M. D., Kuhstoss, S. A., Harvey, A. K., Sato, M., & Aspenberg, P. (2013) · Journal of Orthopaedic Research® · doi:10.1002/jor.22525 · Cited by 22
“formation [2, 6, 7] and causes Sclerosteosis and Van Buchems disease [2, 8-10].”
BackgroundSpatiotemporal Expression of Sclerostin in Odontoblasts during Embryonic Mouse Tooth Morphogenesis
Naka, T., & Yokose, S. (2011) · Journal of Endodontics · doi:10.1016/j.joen.2010.11.025 · Cited by 21
Cao, Y., Wang, B., Wang, D., Zhan, D., Mai, C., Wang, P., Wei, Q., Liu, Y., Wang, H., He, W., et al. (2019) · International Journal of Genomics · doi:10.1155/2019/7076513 · Cited by 24
Xu, X.-J., Shen, L., Yang, Y., Lu, F., Zhu, R., Shuai, B., Cheng-gang, L. I., & Wu, M.-X. (2013) · Chinese Medical Journal · doi:10.3760/cma.j.issn.0366-6999.20130104 · Cited by 27
“In humans, the significance of sclerostin is highlighted by two genetic disorders namely: sclerosteosis and van Buchem’s disease.(6,7) In addition, circulating sclerostin levels were reported to highly correlate with bone marrow plasma sclerostin levels, suggesting that peripheral sclerostin levels likely do accuratel…”
BackgroundDickkopf-1 and Sclerostin Serum Levels in Patients with Systemic Mastocytosis
Rossini, M., Viapiana, O., Zanotti, R., Tripi, G., Perbellini, O., Idolazzi, L., Bonifacio, M., Adami, S., & Gatti, D. (2015) · Calcified Tissue International · doi:10.1007/s00223-015-9969-5 · Cited by 21
Next-generation sequencing: a frameshift in skeletal dysplasia gene discovery
Lazarus, S., Zankl, A., & Duncan, E. L. (2013) · Osteoporosis International · doi:10.1007/s00198-013-2443-1 · Cited by 21
“to be responsible for sclerosteosis [11, 12] and Van Buchem disease [13, 14], both rare skeletal dysplasias associated with high bone mass.”
BackgroundThompson, M. L., Jiménez‐Andrade, J. M., & Mantyh, P. W. (2015) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155415626499 · Cited by 21
“Previous studies examining sclerostin levels in latestage OA patients and in a sheep model of OA suggest that declining levels of sclerostin may play a role in the pathological progression of OA by inhibiting cartilage proteolysis and promoting sub-chondral bone sclerosis (Chan et al. 2011).”
BackgroundResultLi, Y., Hamang, M., Lucchesi, J., Bivi, N., Zeng, Q., Adrian, M. D., Raines, S. E., Li, J., Kuhstoss, S. A., Obungu, V. H., et al. (2016) · Bone · doi:10.1016/j.bone.2016.12.003 · Cited by 22
Harnessing the Power of Electronic Health Records and Genomics for Drug Discovery
Krebs, K., & Milani, L. A. (2023) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-051421-111324 · Cited by 20
Piters, E., de Freitas, F., Nielsen, T. L., Andersen, M., Brixen, K., & Hul, W. V. (2011) · Calcified Tissue International · doi:10.1007/s00223-011-9546-5 · Cited by 24
“osis (MIM 269500), which are both characterized by an enormously increased bone mass as a consequence of unrestrained Wnt/b-catenin signaling [16–21].”
BackgroundSclerostin: recent advances and clinical implications
Honasoge, M., Rao, A. D., & Rao, S. D. (2014) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000114 · Cited by 26
Thouverey, C., & Caverzasio, J. (2015) · BoneKEy Reports · doi:10.1038/bonekey.2015.126 · Cited by 22
“On the basis of the presence of a cystine-knot motif in its structure, sclerostin has been ranked in the DAN (differential screening selected gene abberative in neuroblastoma) family of secreted glycoproteins that share the ability to antagonize bone morphogenetic protein (BMP) activity.(1,3) As sclerostin inhibits BM…”
BackgroundRecent Discoveries in Monogenic Disorders of Childhood Bone Fragility
Mäkitie, R. E., Kämpe, A. J., Taylan, F., & Mäkitie, O. (2017) · Current Osteoporosis Reports · doi:10.1007/s11914-017-0388-6 · Cited by 20
Sclerosteosis: Report of type 1 or 2 in three Indian Tamil families and literature review
Whyte, M. P., Amalnath, S. D., McAlister, W. H., Radhakrishna, P., Vivekanandan, M., Duan, S., Huskey, M., Bijanki, V. N., & Mumm, S. R. (2018) · Bone · doi:10.1016/j.bone.2018.07.022 · Cited by 20
Campos, G. S., Sollero, B. P., Reimann, F. A., Junqueira, V. S., Cardoso, L. L., Yokoo, M. J. I., Boligon, A. A., Neto, J. B., & Cardoso, F. F. (2019) · Journal of Animal Breeding and Genetics · doi:10.1111/jbg.12458 · Cited by 20
Romosozumab in the Treatment of Osteoporosis
Kobza, A. O., Παπαϊωάννου, Α., Lau, A. N., & Adachi, J. D. (2020) · Immunotherapy · doi:10.2217/imt-2020-0158 · Cited by 20
Osteocytes and the pathogenesis of hypophosphatemic rickets
Yamazaki, M., & Michigami, T. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1005189 · Cited by 23
“SOST was identified as the causative gene for sclerosteosis 1 (MIM #269500) and van Buchem disease (MIM #239100), which are characterized by a high bone mass, indicating that osteocytes regulate bone mass by producing sclerostin (6, 7).”
BackgroundBalemans, W., & Hul, W. V. (2006) · PubMed · Cited by 20
Chan, W. C. W., Tsang, K. Y., Cheng, Y., Ng, V. C. W., Chik, H., Tan, Z., Boot-Handford, R., BOYDE, A., Cheung, K., Cheah, K. S. E., et al. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx339 · Cited by 20
Normal growth and development in mice over‐expressing the CCN family member WISP3
Nakamura, Y., Cui, Y., Fernando, C. A., Kutz, W. E., & Warman, M. L. (2009) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-009-0040-z · Cited by 20
“One of these domains, a carboxy-terminal cystine knot, is also found in several known BMP and Wnt signaling modulators such as Noggin, SOST, and WISE, as well as in members of the TGF-β superfamily (Piccolo et al. 1999; Brunkow et al. 2001; Brigstock 2003; Itasaki et al. 2003; Avsian-Kretchmer and Hsueh 2004; Perbal 2…”
BackgroundImamura, K., Maeda, S., Kawamura, I., Matsuyama, K., Shinohara, N., Yahiro, Y., Nagano, S., Setoguchi, T., Yokouchi, M., Ishidou, Y., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.520585 · Cited by 19
“, LDL receptor-related protein 5 (Lrp5), sclerostin (Sost), and human immunodeficiency virus type I enhancer binding protein 3 (Hivep3), have been found to control osteoblast function in the adult human and/or mouse during postnatal skeletal remodeling (6-10).”
BackgroundSchoeman, M. A. E., Moester, M. J. C., Oostlander, A. E., Kaijzel, E. L., Valstar, E. R., Nelissen, R. G. H. H., Löwik, C. W. G. M., & de Rooij, K. E. (2015) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25241 · Cited by 21
“Mutations in the gene encoding sclerostin, SOST, or the surrounding regulatory regions lead to sclerostin deficiency and bone overgrowth in sclerosteosis and van Buchem disease, respectively [van Hul et al., 1998; Brunkow et al., 2001; Loots et al., 2005; Moester et al., 2010].”
BackgroundSclerostin monoclonal antibodies on bone metabolism and fracture healing
Gamie, Z., Korres, N., Leonidou, A. O., Gray, A. C., & Tsiridis, E. E. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.713936 · Cited by 21
“Mutations described in the sclerosteosis (SOST) [23] and LRP5 genes [24] have been associated with a high bone mass phenotype.”
BackgroundCommon and rare variants of WNT16, DKK1 and SOST and their relationship with bone mineral density
Martínez‐Gil, N., Roca‐Ayats, N., Monistrol-Mula, A., García‐Giralt, N., Díez‐Pérez, A., Nogués, X., Mellibovsky, L., Grinberg, D., & Balcells, S. (2018) · Scientific Reports · doi:10.1038/s41598-018-29242-8 · Cited by 19
Wang, J., Qiu, X., Xu, T., Sheng, Z., & Yao, L. (2019) · Blood Purification · doi:10.1159/000496219 · Cited by 19
Lim, K., Bullock, W. A., Horan, D. J., Williams, B. O., Warman, M. L., & Robling, A. G. (2020) · Bone · doi:10.1016/j.bone.2020.115708 · Cited by 19
Yamamoto, T., Ikegame, M., Hirayama, J., Kitamura, K.-I., Tabuchi, Y., Furusawa, Y., Sekiguchi, T., Endo, M., Mishima, H., Seki, A., et al. (2020) · Biomedical Research · doi:10.2220/biomedres.41.279 · Cited by 19
“Mutations in Sost are associated with bone diseases characterized by high bone mass, such as sclerosteosis and Van Buchem disease (Balemans et al. 2001; Brunkow et al. 2001; Balemans et al. 2002; Staehling-Hampton et al. 2002).”
BackgroundDecreased Sclerostin Secretion in Humans and Mice With Nonalcoholic Fatty Liver Disease
Zhou, F., Wang, Y., Li, Y., Tang, M., Wan, S., Tian, H., & Chen, X. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.707505 · Cited by 19
“suggested that sclerostin expression levels in human and mouse liver were only lower than those of bone and cartilage (21).”
BackgroundThe promise of sclerostin inhibition for the treatment of osteoporosis
Kneissel, M. (2009) · IBMS BoneKEy · doi:10.1138/20090388 · Cited by 20
“A lack of sclerostin expression in mature osteocytes results in a progressive, generalized, massive bone mass increase due to high bone formation in humans and mice (1-3), suggesting that inhibition of this secreted glycoprotein might restore bone mass and thus strength to the osteoporotic skeleton.”
BackgroundResultInfluentialProvot, S., Schipani, E., Wu, J. Y., & Kronenberg, H. M. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-415853-5.00006-6 · Cited by 24
Nicol, L. E., Wang, Y., Smith, R. C., Sloan, J. H., Nagamani, S. C. S., Shapiro, J. R., Lee, B., & ORWOLL, E. S. (2017) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3312 · Cited by 19
Serum Sclerostin Level and Bone Mineral Density in Pediatric Hemophilic Arthropathy
Mikkawy, D. M. E. E., El-Badawy, M. A., El-Ghany, S. M. A., & Samaha, D. Y. (2019) · The Indian Journal of Pediatrics · doi:10.1007/s12098-019-02855-1 · Cited by 20
New treatments for osteoporosis
(1990) · The Lancet · doi:10.1016/0140-6736(90)92635-u · Cited by 21
Emerging therapies in metastatic bone pain
Coluzzi, F., Mandatori, I., & Mattia, C. (2011) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2011.576668 · Cited by 19
“DKK-1 acts on LRP5/6 co-receptor activity and disrupts osteoblast differentiation and action [127].”
BackgroundInfluentialWise Regulates Bone Deposition through Genetic Interactions with Lrp5
Ellies, D. L., Economou, A., Viviano, B. L., Rey, J., Paine‐Saunders, S., Krumlauf, R. K., & Saunders, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096257 · Cited by 21
“Based on its weak similarity to the DAN and CCN family of cystein knot proteins, which themselves bind BMPs, Sclerostin has been postulated to exert its function in regulating bone density via its biochemical ability to bind BMPs and inhibit signaling [25,27,28].”
BackgroundAnti-sclerostin – is there an indication?
Larsson, S. (2016) · Injury · doi:10.1016/s0020-1383(16)30008-0 · Cited by 18
Treatment with anti‐Sclerostin antibody to stimulate mandibular bone formation
Tamplen, M. L., Fowler, T. W., Markey, J., Knott, P. D., Suva, L. J., & Alliston, T. N. (2018) · Head & Neck · doi:10.1002/hed.25128 · Cited by 18
“Sclerostin was identified by studying the loss-of-function mutation in patients with the rare genetic disorder Sclerosteosis.(1,4,5,7) Sclerosteosis is characterized by extremely high bone mass throughout the skeleton, tall stature, and enlarged jaws.”
BackgroundCompetitive blocking of LRP4–sclerostin binding interface strongly promotes bone anabolic functions
Katchkovsky, S., Chatterjee, B., Abramovitch-Dahan, C.-V., Papo, N., & Levaot, N. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04127-2 · Cited by 20
Regulation of Sclerostin Expression by Paracrine and Endocrine Factors
Sims, N. A., & Chia, L. Y. (2011) · Clinical Reviews in Bone and Mineral Metabolism · doi:10.1007/s12018-011-9121-7 · Cited by 20
“While most work to date has focused on the osteocytic expression of sclerostin, sclerostin mRNA has been detected in other organs in human and mouse, including kidney, lung and heart [1, 3, 6], in vascular smooth muscle cells [13] and human and murine chondrocytes [3, 14].”
BackgroundValidation of a novel, rapid, high precision sclerostin assay not confounded by sclerostin fragments
Drake, M. T., Fenske, J. S., Blocki, F. A., Zierold, C., Appelman‐Dijkstra, N. M., Papapoulos, S. E., & Khosla, S. (2018) · Bone · doi:10.1016/j.bone.2018.03.013 · Cited by 18
“Mutations in SOST, the gene encoding sclerostin, have been identified as the causative defect in patients with the rare high bone mass disorder sclerosteosis [2, 3].”
BackgroundModulation of matrix mineralization by Vwc2-like protein and its novel splicing isoforms
Ohyama, Y., Katafuchi, M., Almehmadi, A. H., Venkitapathi, S., Jaha, H., Ehrenman, J. S., Morcos, J. M., Aljamaan, R., & Mochida, Y. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.12.075 · Cited by 18
“To date, a number of CKP family members have been cloned and their potential functions in mineralized tissues were characterized [32,33,34,35].”
BackgroundNephroblastoma Overexpressed (Nov) Is a Novel Bone Morphogenetic Protein Antagonist
CANALIS, E. M. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1402.055 · Cited by 18
Mace, M. L., Gravesen, E., Nordholm, A., Egstrand, S., Morevati, M., Ølgaard, K., & Lewin, E. (2022) · JBMR Plus · doi:10.1002/jbm4.10610 · Cited by 17
“Osteocytes secrete sclerostin, which is an essential factor in balancing bone formation and resorption.((40,43,44)) In the present study we showed upregulation of Sost gene in the calcified aorta from uremic rats, which also secreted sclerostin in high amounts, like our previous results.”
ResultHigh Bone Mass Disorders: New Insights From Connecting the Clinic and the Bench
Bergen, D. J. M., Maurizi, A., Formosa, M. M., McDonald, G. L. K., El‐Gazzar, A., Hassan, N., Brandi, M. L., Riancho, J. A., Rivadeneira, F., Ntzani, E., et al. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4715 · Cited by 18
“A prominent example of such success was the discovery of loss-of-function (LoF) mutations in SOST encoding sclerostin in families with sclerosteosis (OMIM 269500) and van Buchem disease (OMIM 239100), two severe HBM conditions.((6-8)) A concerted multidisciplinary research effort then unraveled the precise function an…”
BackgroundSclerostin in CKD-MBD: one more paradoxical bone protein?
Jean, G., & Chazot, C. (2013) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft222 · Cited by 17
“Patients with sclerosteosis or hyperostosis, who inherited high bone mass, were found to have a mutation of the SOST gene that impairs sclerostin activity [9].”
BackgroundOsteoarthritis: Insights Offered by the Study of Bone Mass Genetics
Hartley, A. E., Gregson, C. L., Paternoster, L., & Tobias, J. H. (2021) · Current Osteoporosis Reports · doi:10.1007/s11914-021-00655-1 · Cited by 18
Genetic Analysis of High Bone Mass Cases from the BARCOS Cohort of Spanish Postmenopausal Women
Sarrión, P., Mellibovsky, L., Urreizti, R., Civit, S., Cols, N., García‐Giralt, N., Yoskovitz, G., Aranguren‐Ibáñez, Á., Malouf, J., Gregorio, S. D., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094607 · Cited by 18
Gene therapy for in vivo bone formation: recent advances.
Lattanzi, W., Pola, E., Pecorini, G., Logroscino, C. A., & Robbins, P. D. (2005) · PubMed · Cited by 18
Watanabe, T., Tamamura, Y., Hoshino, A., Makino, Y., Kamioka, H., Amagasa, T., Yamaguchi, A., & Iimura, T. (2012) · Bone · doi:10.1016/j.bone.2012.06.019 · Cited by 20
“Loss-of-function mutations in the SOST gene, which encodes sclerostin, cause sclerosteosis or Van Buchem disease, which are both associated with a high bone mass and thickened bone [34–37], and are consistentwith the phenotype observed following targeted deletion of themouse SOST [38].”
BackgroundN‐cadherin restrains PTH repressive effects on sclerostin/SOST by regulating LRP6–PTH1R interaction
Yang, H., Dong, J., Xiong, W., Fang, Z., Guan, H., & Li, F. (2016) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13221 · Cited by 18
New treatments of osteoporosis
Langdahl, B. L. (2015) · Osteoporosis and Sarcopenia · doi:10.1016/j.afos.2015.07.007 · Cited by 17
Genetics of Osteoporosis: Perspectives for Personalized Medicine
Li, W., Hou, S.-X., Yu, B., Jin, D., Férec, C., & Chen, J. (2010) · Personalized Medicine · doi:10.2217/pme.10.55 · Cited by 20
Bone signaling pathways and treatment of osteoporosis
Gogakos, A. I., Cheung, M., Bassett, J. H. D., & Williams, G. R. (2009) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.09.38 · Cited by 21
How genomics has informed our understanding of the pathogenesis of osteoporosis
Johnson, M. L., Lara, N., & Kamel, M. A. (2009) · Genome Medicine · doi:10.1186/gm84 · Cited by 18
“: Genome Medicine 2009, 1:84 Another important family-based gene discovery that also relates to the Wnt/β-catenin signaling pathway was the identification of the SOST gene and its role in the pathogenesis of sclerosteosis [42-44] and van Buchem’s disease [45,46].”
BackgroundLRP5, Bone Mass Polymorphisms and Skeletal Disorders
Littman, J., Yang, W., Olansen, J., Phornphutkul, C., & Aaron, R. K. (2023) · Genes · doi:10.3390/genes14101846 · Cited by 17
Thompson, M. L., Chartier, S. R., Mitchell, S. A. T., & Mantyh, P. W. (2016) · Molecular Pain · doi:10.1177/1744806916677147 · Cited by 16
The Osteocyte Transcriptome: Discovering Messages Buried Within Bone
Wee, N. K. Y., Sims, N. A., & Morello, R. (2021) · Current Osteoporosis Reports · doi:10.1007/s11914-021-00708-5 · Cited by 16
Karampatsou, S., Paltoglou, G., Genitsaridi, S. M., Kassari, P., & Charmandari, E. (2022) · Nutrients · doi:10.3390/nu14183772 · Cited by 16
“Sclerostin was first described as a protein produced by the SOST gene and its deficiency results in sclerosteosis, a disorder characterized by extreme bone overgrowth [25].”
BackgroundSclerostin Declines during Hemodialysis and Appears in Dialysate
Bielesz, B. O., Hempfing, T., Kieweg, H., Marculescu, R., Haas, M., & Cejka, D. (2014) · Blood Purification · doi:10.1159/000364992 · Cited by 16
Sclerostin and the Unloading of Bone
Suva, L. J. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090815 · Cited by 16
“ated with an autosomal-recessive disorder, sclerosteosis, which causes progressive bone overgrowth.((4,5)) A deletion downstream of this gene, which results in reduced sclero-”
BackgroundGenes and Molecular Pathways of the Osteogenic Process
Lattanzi, W., & Bernardini, C. (2012) · InTech eBooks · doi:10.5772/34022 · Cited by 17
“as sclerosteosis (MIM#269500; Brunkow et al., 2001).”
Boschert, V., Frisch, C. M., Back, J. W., van Pee, K., Weidauer, S. E., Muth, E.-M., Schmieder, P., Beerbaum, M., Knappik, A., Timmerman, P., et al. (2016) · Open Biology · doi:10.1098/rsob.160120 · Cited by 16
“Sclerosteosis patients lack sclerostin due to homozygous mutations in the sclerostinencoding gene SOST [2,5], but heterozygous carriers have an increased bone mineral density suggesting a gene dosage effect for sclerostin [6].”
TIEG and estrogen modulate SOST expression in the murine skeleton
Subramaniam, M., Pitel, K. S., Bruinsma, E. S., Monroe, D. G., & Hawse, J. R. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.26211 · Cited by 16
“Mutations in, or deletion of, the SOST gene are known to cause a high bone mass phenotype in mice and humans (Balemans et al., 2001; Brunkow et al., 2001; Li et al., 2008).”
BackgroundWesenbeeck, L. V., Odgren, P. R., MacKay, C. A., & Hul, W. V. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2004.19.2.183 · Cited by 17
“Sclerostin, encoded by the SOST gene, acts as a negative regulator of bone formation, most likely by inhibiting bone morphogenetic protein signaling.((32,33)) The receptor activity-modifying protein 2 (RAMP2) interacts with calcitonin receptor-like receptor to form a heterodimeric complex, which forms an additional re…”
Background
Metadata
- Authors
- Brunkow, M. E., Gardner, J. C., Van Ness, J., Paeper, B. W., Kovacevich, B. R., Proll, S., Skonier, J. E., Zhao, L., Sabo, P. J., Fu, Y.-H., Alisch, R. S., Gillett, L., Colbert, T., Tacconi, P., Galas, D., Hamersma, H., Beighton, P., & Mulligan, J. T.
- Affiliations
- University of Cape Town (ZA)
- University of Cagliari (IT)
- Corresponding author
- Brunkow, Mary E.
- ORCID
- Venue
- The American Journal of Human Genetics
- Publisher
- Elsevier BV
- Published
- 2001-03
- Volume
- 68
- Issue
- 3
- Pages
- 577-589
- ISSN
- 0002-9297 (ISSN-L)
- PMC
- PMC1274471
- OpenAlex
- W2037750372
- Cited by
- 1,011
- References
- 50
- Citations by year
- 2026: 24 · 2025: 21 · 2024: 32 · 2023: 27 · 2022: 36 · 2021: 53 · 2020: 52 · 2019: 46 · 2018: 50 · 2017: 56 · 2016: 65 · 2015: 61 · 2014: 58 · 2013: 60 · 2012: 56
- FWCI
- 7.00
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 4523 d)
- Locations
- The American Journal of Human Genetics (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Dermatological and Skeletal Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Connective tissue disorders research
- Keywords
- sclerosteosis, SOST gene, skeletal dysplasia, cystine knot proteins, bone homeostasis, skeletal overgrowth, nonsense mutation, splicing mutation, founder effect, Afrikaner population, bone formation regulation
- MeSH terms
- Amino Acid Sequence, Animals, Base Sequence, Bone Diseases, Chromosome Mapping, Chromosomes, Human, Pair 17, Consanguinity, Cystine, Female, Genetic Markers, Homozygote, Humans, Male, Molecular Sequence Data, Netherlands, Pedigree, Proteins, Recombination, Genetic, Sclerosis, Senegal, South Africa, Conserved Sequence, Alternative Splicing, Bone Morphogenetic Proteins, Mutation, Missense, Black People, White People, Adaptor Proteins, Signal Transducing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.